Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-11
2010-02-23
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S021800, C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
07666838
ABSTRACT:
The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.
REFERENCES:
patent: 5998204 (1999-12-01), Tsien et al.
patent: 6921748 (2005-07-01), O'Harte et al.
patent: 7326688 (2008-02-01), O'Harte et al.
patent: 196 16 486 (1997-10-01), None
patent: 0 869 135 (1998-10-01), None
patent: WO 00/58360 (2000-10-01), None
Conlon et al. Primary Structure of glucagon from the gut of the common dogfish . . . FEBS Letters. Apr. 1987, vol. 214, No. 1, pp. 50-56.
Demuth, et al.,Chemical Abstracts127:69 abstract 341803D (1997).
Fujii et al.,Chem. Pharm. Bull. 34(6):2397-2410 (1986) “Studies on Peptides. CXXXIX. Solution synthesis of a 42-residue peptide corresponding to the entire amino acid sequence of human glucose-dependent insulinotropic polypeptide (GIP)”.
Gallwitz et al.,J. Mol. Endocrinology10:259-268 (1993) “Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells”.
Gallwitz et al.,Regulatory Peptides63:17-22 (1996) “GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1”.
Gault et al.,Digestion60:504-505 (1999) “Stability of GIP and Amino-Terminally Modified GIP Analogues to DPP IV and Human Plasma,” Scientific Meeting of the Bayliss & Starling Society, Belfast, N. Ireland, Sep. 5-8, 1999.
Gelling et al., “Minor N-terminal modification of glucose-dependent insulinotropic polypeptide (GIP) greatly reduces receptor binding and insulinotropic activity: evidence that N-terminal residues are essential for biological activity,” Abstract P2-29, Tenth International Congress of Endocrinology, Jun. 12-13, 1996, San Francisco, USA.
Gelling et al.,Endocrinology138:2640-2643 (1997) “Localization of the domains involved in ligand binding and activation of the glucose-dependent insulin tropic polypeptide receptor”.
Gelling et al.,Regulatory Peptides69:151-154 (1997) “GIP6-30amidecontains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42action in vitro”.
Gelling, Ph.D. Thesis, Oct. 1998, “Structure-function studies of the gastric inhibitory polypeptide/glucose dependent insulinotropic polypeptide (GIP) receptor”.
Jornvall et al.,FEBS Letters123:205-210 (1981) “Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)”.
Kühn-Wache et al., “Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance,” in Cellular Peptidases in Immune Functions and Diseases 2, Proceedings of an international conference. Sep. 12-14, 1999, Magdeburg-Herrenkrug, Germany, ed. Langer & Ansorge, Kluwer Academic/Plenum Publishers, 2000.
Kurtzhals et al.,Biochem. J. 312:725-731 (1995) “Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo”.
McIntosh et al.,Acta Physiol. Scand. 157:361-365 (1996) “GIP receptors and signal-transduction mechanisms”.
Mentlein,FEBS Letters234:251-256 (1988) “Proline residues in the maturation and degradation of peptide hormones and neuropeptides”.
Mentlein et al.,Eur. J. Biochem. 214:829-835 (1993) “Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum”.
Mooney et al.,Digestion60:505 (1999) “Effect of Tyr1-Glucitol GIP on Insulin Release and Glucose Homeostasis in Obese Diabetic Mice,” Scientific Meeting of the Bayliss & Starling Society, Belfast, N. Ireland, Sep. 5-8, 1999.
O'Harte et al.,Biochim. Biophys. Acta. 1425:319-327 (1998) “Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells”.
O'Harte et al.,Chemical Abstracts131:122 (1999) “NH2—terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced anti-hyperglycemic activity”, (was cited in parent patent).
O'Harte et al.,Diabetes48:758-765 (1999) “NH2-terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced anti-hyperglycemic activity”.
O'Harte et al.,J. Endocrinology165:639-648 (2000) “Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.”
Rossowski et al.,Regulatory Peptides39:9-17 (1992) “Reduced gastric acid inhibitory effect of a pGIP(1-30)NH2fragment with potent pancreatic amylase inhibitory activity”.
Schmidt et al.,Endocrinology120:835-837 (1987) “Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39”.
Flatt Peter Raymond
O'Harte Finbarr Paul
K & L Gates LLP
Russel Jeffrey E
UUTech Limited
LandOfFree
Analogs of gastric inhibitory polypeptide and their use for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analogs of gastric inhibitory polypeptide and their use for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogs of gastric inhibitory polypeptide and their use for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155451